Leerink Partnrs Has Weak Forecast for Opthea FY2025 Earnings

Opthea Limited (NASDAQ:OPT) – Equities research analysts at Leerink Partnrs cut their FY2025 EPS estimates for shares of Opthea in a research note issued to investors on Monday, March 24th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn ($1.62) per share for the year, down from their prior estimate of ($1.15). Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Opthea’s current full-year earnings is ($1.39) per share. Leerink Partnrs also issued estimates for Opthea’s FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.41) EPS and FY2028 earnings at ($0.37) EPS.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright downgraded shares of Opthea from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $12.00 to $2.00 in a research report on Tuesday. Canaccord Genuity Group raised Opthea to a “strong-buy” rating in a report on Tuesday, December 17th. Jefferies Financial Group reiterated an “underperform” rating and set a $1.00 price target (down from $8.00) on shares of Opthea in a research report on Tuesday. Oppenheimer lowered Opthea from an “outperform” rating to a “market perform” rating in a research report on Monday. Finally, Leerink Partners lowered Opthea from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $12.00 to $1.00 in a research report on Tuesday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $1.33.

Opthea Trading Up 7.2 %

OPT stock opened at $3.41 on Thursday. Opthea has a 1-year low of $1.79 and a 1-year high of $6.30. The firm has a fifty day moving average price of $4.41 and a two-hundred day moving average price of $4.06.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. ABC Arbitrage SA acquired a new stake in Opthea in the fourth quarter worth about $40,000. OLD Mission Capital LLC bought a new stake in shares of Opthea during the 4th quarter worth about $42,000. Twin Lakes Capital Management LLC acquired a new stake in shares of Opthea in the 3rd quarter worth approximately $81,000. Citadel Advisors LLC bought a new position in shares of Opthea in the fourth quarter valued at approximately $79,000. Finally, Jane Street Group LLC acquired a new position in shares of Opthea during the third quarter valued at approximately $114,000. Institutional investors own 55.95% of the company’s stock.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.